Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02508805 | Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy | PHASE3 | COMPLETED | 100 | — | — | May 1, 2015 | Nov 1, 2015 | May 9, 2017 | 1 | Russia |
Self reported pain intensity over the last 24 hours. The amount of pain is marked on a horizontal line at a certain point which reflects pain perception best: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
| Arm | Type | Description |
|---|---|---|
| Neuromultivit +Voltaren+Sirdalud | EXPERIMENTAL | Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days. Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days. |
| Voltaren+Sirdalud alone | ACTIVE_COMPARATOR | Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days |
| Name | Type | Description |
|---|---|---|
| Neuromultivit | DRUG | - |
| Voltaren | DRUG | - |
| Sirdalud | DRUG | - |
Inclusion Criteria: * diagnosed vertebrogenic radiculopathy L5, S1 * radicular pain syndrome * changes in the low back CT and MRI scans * minimum 40 mm intensity of spontaneous back pain, rated on the VA scale * 1 month exacerbation phase; nonuse of any B-group vitamins before the trial * negative ...